A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women (LAE102)
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Phase 1 Study to Determine the Safety, Tolerability and Pharmacokinetics of LAE102 in Healthy Postmenopausal Women
Sponsor: Eli Lilly and Company
A PHASE1 clinical study on Healthy Adult Female Participants and Postmenopausal, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 4 data snapshots since 2025. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
4 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Oct 2025 — Dec 2025 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2025 — Oct 2025 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2025 — Jun 2025 [monthly]
Not Yet Recruiting PHASE1
First recorded
Apr 2025
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
- Laekna Limited
For direct contact, visit the study record on ClinicalTrials.gov .